ArticleArchives of medical science : AMS2013
Treatment of non-ST-elevation myocardial infarction and ST-elevation myocardial infarction in patients with chronic kidney disease.
Article in Archives of medical science : AMS, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 30 citations in OpenAlex.
- Anti-Inflammatory and Antiplatelet Interactions on PAF and ADP Pathways of NSAIDs, Analgesic and Antihypertensive Drugs for Cardioprotection-In Vitro Assessment in Human Platelets.Medicina (Kaunas, Lithuania) · 2025Article
- Characteristics of calcified nodule attributable to culprit lesion in acute coronary syndrome: A systematic review and meta-analysis.iScience · 2024Article
- Incidence and predictors of recurrent acute coronary syndrome among adult patients with acute coronary syndrome in West Amhara, Ethiopia: a multicenter retrospective follow-up study.Frontiers in cardiovascular medicine · 2023Article
- Dose-dependent effect of impaired renal function on all-cause mortality in patients following percutaneous coronary intervention.Clinical cardiology · 2022Article
- Efficacy and Safety of the Reduced Bivalirudin in Patients Undergoing Coronary Angiography or Percutaneous Coronary Intervention Stratified by Renal Function (REDUCE BOLUS): A Single-Blind, Stratified Randomized, Non-inferiority Trial.Frontiers in cardiovascular medicine · 2022Article
- Effects of renal impairment on cardiac remodeling and clinical outcomes after myocardial infarction.International journal of medical sciences · 2021Article
- Expression of miRNAs-122, -192 and -499 in end stage renal disease associated with acute myocardial infarction.Archives of medical science : AMS · 2019Article
- Fibroblast growth factor 23, iron and inflammation - are they related in early stages of chronic kidney disease?Archives of medical science : AMS · 2017Article
- Clinical SYNTAX Score - a good predictor for renal artery stenosis in acute myocardial infarction patients: analysis from the REN-ACS trial.Archives of medical science : AMS · 2017Article
- Biochemical markers of type 2 diabetes as a late complication of myocardial infarction: a case-control study.Archives of medical science : AMS · 2017Article
- Neutrophil-to-lymphocyte ratio as a possible indicator of epicardial adipose tissue in patients undergoing hemodialysis.Archives of medical science : AMS · 2017Article
- The Relationship Between Hemodialysis and the Echocardiographic Findings in Patients with Chronic Kidney Disease.Medical archives (Sarajevo, Bosnia and Herzegovina) · 2016Article
- Is kidney function affecting the management of myocardial infarction? A retrospective cohort study in patients with normal kidney function, chronic kidney disease stage III-V, and ESRD.International journal of nephrology and renovascular disease · 2016Article
- Lipids, blood pressure and kidney update 2015.Lipids in health and disease · 2015Review
- Iron metabolism in hemodialyzed patients - a story half told?Archives of medical science : AMS · 2014Article
- Heart function disturbances in chronic kidney disease - echocardiographic indices.Archives of medical science : AMS · 2014Article
- Markers of increased cardiovascular risk in patients with chronic kidney disease.Lipids in health and disease · 2014Article
- Review
- Lipid, blood pressure and kidney update 2013.International urology and nephrology · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Renal dysfunction is frequent in patients with non-ST-segment elevation acute coronary syndrome (NSTE-ACS). Chronic kidney disease (CKD) is associated with very poor prognosis and is an independent predictor of early and late mortality and major bleeding in patients with NSTE-ACS. Patients with NSTE-ACS and CKD are still rarely treated according to guidelines. Medical registers reveal that patients with CKD are usually treated with too high doses of antithrombotics, especially anticoagulants and inhibitors of platelet glycoprotein (GP) IIb/IIIa receptors, and therefore they are more prone to bleeding. Drugs which are excreted mainly or exclusively by the kidney should be administered in a reduced dose or discontinued in patients with CKD. These drugs include enoxaparin, fondaparinux, bivalirudin, and small molecule inhibitors of GP IIb/IIIa inhibitors. In long-term treatment of patients after myocardial infarction, anti-platelet therapy, lipid-lowering therapy and β-blockers are used. Chronic kidney disease patients before qualification for coronary interventions should be carefully selected in order to avoid their use in the group of patients who could not benefit from such procedures. This paper presents schemes of non-ST and ST-segment elevation myocardial infarction treatment in CKD patients in accordance with the current recommendations of the European Society of Cardiology (ESC).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.